Published in Sci Rep on July 14, 2016
Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med (2001) 46.58
Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and lamm equation modeling. Biophys J (2000) 21.93
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
LPS/TLR4 signal transduction pathway. Cytokine (2008) 6.60
Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA (2014) 6.11
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med (2003) 4.04
Animal models of sepsis and sepsis-induced kidney injury. J Clin Invest (2009) 2.71
Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution. EMBO J (1993) 2.15
Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis (2011) 1.74
Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci (2007) 1.47
The macrophage response towards LPS and its control through the p38(MAPK)-STAT3 axis. Cell Signal (2012) 1.40
Prevention of endotoxin-induced monokine release by human low- and high-density lipoproteins and by apolipoprotein A-I. Infect Immun (1993) 1.39
Decreasing mortality in severe sepsis and septic shock patients by implementing a sepsis bundle in a hospital setting. PLoS One (2011) 1.35
Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science (1993) 1.23
Extrinsic and intrinsic control of macrophage inflammatory responses. J Leukoc Biol (2013) 1.23
Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules. J Mol Recognit (2001) 1.19
Monocytes/macrophages and sepsis. Crit Care Med (2005) 1.17
Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci (2013) 1.15
The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol (1998) 1.06
Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.05
Determination of critical micelle concentrations and aggregation numbers by fluorescence correlation spectroscopy: aggregation of a lipopolysaccharide. Anal Chim Acta (2005) 1.04
Zwitterionic chitosan derivatives for pH-sensitive stealth coating. Biomacromolecules (2010) 1.00
Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg Med Chem (2005) 0.99
The effect of water-soluble chitosan on macrophage activation and the attenuation of mite allergen-induced airway inflammation. Biomaterials (2008) 0.98
Interaction of cationic amphiphilic drugs with lipid A: implications for development of endotoxin antagonists. Biochim Biophys Acta (1994) 0.93
Zwitterionic chitosan derivative, a new biocompatible pharmaceutical excipient, prevents endotoxin-mediated cytokine release. PLoS One (2012) 0.92
Mechanisms of endotoxin neutralization by synthetic cationic compounds. J Endotoxin Res (2006) 0.91
Novel therapies for sepsis: antiendotoxin therapies. Expert Opin Investig Drugs (2002) 0.91
Endotoxin removal by affinity sorbents. J Biochem Biophys Methods (2001) 0.90
Chitosan oligosaccharides inhibit the expression of interleukin-6 in lipopolysaccharide-induced human umbilical vein endothelial cells through p38 and ERK1/2 protein kinases. Basic Clin Pharmacol Toxicol (2009) 0.88
Immunotherapy of endotoxemia and septicemia. Immunobiology (1993) 0.86
Peptide-based treatment of sepsis. Appl Microbiol Biotechnol (2011) 0.85
Zwitterionic chitosan-polyamidoamine dendrimer complex nanoparticles as a pH-sensitive drug carrier. Mol Pharm (2013) 0.82
Anti-lipid A monoclonal antibody centoxin (HA-1A) binds to a wide variety of hydrophobic ligands. Infect Immun (1998) 0.81
Development of an anti-endotoxin vaccine for sepsis. Subcell Biochem (2010) 0.80
In vitro toxicity of colistin on primary chick cortex neurons and its potential mechanism. Environ Toxicol Pharmacol (2013) 0.80
Forming and immunological properties of some lipopolysaccharide-chitosan complexes. Biochimie (2005) 0.79
Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer. Biomaterials (2014) 0.78
Extracellularly activatable nanocarriers for drug delivery to tumors. Expert Opin Drug Deliv (2014) 0.77
Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev (2015) 0.76
Stabilization of a hyaluronate-associated gene delivery system using calcium ions. Biomater Sci (2015) 0.75
Tannic acid-mediated surface functionalization of polymeric nanoparticles. ACS Biomater Sci Eng (2016) 0.75
Small molecule delivery to solid tumors with chitosan-coated PLGA particles: A lesson learned from comparative imaging. J Control Release (2017) 0.75